Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCLC | P48506 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338990 | 0.98 | GABRR1 (0.38) | GCLCGABRR1CYP1A2GRM3GABBR2 | |
| SCHEMBL2402598 | 0.86 | GRM3 (0.45) | GABRR1CYP1A2GRM3ANPEPLAP3 | |
| SCHEMBL340077 | 0.81 | GCLC (0.43) | GCLCGABRR1CYP1A2ACE2FDPS | |
| SCHEMBL339921 | 0.80 | GRM3 (0.41) | GABRR1CYP1A2GRM3ANPEPLAP3 | |
| SCHEMBL2403991 | 0.78 | MMP1 (0.37) | GABBR2GABBR1FDPS | |
| SCHEMBL339782 | 0.78 | GABBR2 (0.47) | GCLCGABRR1GABBR2GABBR1ACE2 | |
| SCHEMBL2992987 | 0.77 | GABRR1 (0.39) | GABRR1CYP1A2ACE2ANPEPLAP3 | |
| Hydrochloric Acid SCHEMBL11700096 | 0.77 | GABBR2 (0.33) | GABBR2GABBR1FDPS | |
| SCHEMBL338963 | 0.77 | GCLC (0.40) | GCLCGABRR1CYP1A2GRM3 | |
| SCHEMBL1304832 | 0.77 | FOLH1 (0.48) | GABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735477-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-05-27 | — | — | US | disclosed |
| US-20110213060-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213060-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | AOC2, AOC3, SCO2 | GCLC 2510/4885GABRR1 3289/4885CYP1A2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.